Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-389P (RNA, U6 small nuclear 389, pseudogene) is a non-coding RNA pseudogene in the human genome[1][2][6]. It is classified as a *pseudogene* of the U6 family of small nuclear RNAs (snRNAs), specifically denoted as "copynumber 389." U6 snRNAs are essential components of the spliceosome, the large ribonucleoprotein complex responsible for the removal of introns from pre-mRNA during splicing[3][5]. However, as a pseudogene, RNU6-389P does *not* produce a functional RNA product and is neither expected nor reported to encode any protein or participate in biological functions[1][2][6]. It exists in the genome as a non-functional relic of gene duplication or retrotransposition events. There are typically many U6 pseudogenes in vertebrate genomes, reflecting the genomic importance and evolutionary history of the U6 snRNA but not conferring biological function to pseudogenes themselves[5]. There is no evidence supporting a role for RNU6-389P in disease, no interacting drugs, known biomarkers, or safety concerns associated with this molecule. Its designation as a pseudogene means it is *not* a therapeutic target or functional biomolecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 389, pseudogene (RNU6-389P).